BR0012050A - Derivados de purina substituìda como inibidores da adesão celular - Google Patents

Derivados de purina substituìda como inibidores da adesão celular

Info

Publication number
BR0012050A
BR0012050A BR0012050-2A BR0012050A BR0012050A BR 0012050 A BR0012050 A BR 0012050A BR 0012050 A BR0012050 A BR 0012050A BR 0012050 A BR0012050 A BR 0012050A
Authority
BR
Brazil
Prior art keywords
compounds
cell
formula
inhibitors
purine derivatives
Prior art date
Application number
BR0012050-2A
Other languages
English (en)
Inventor
Anuschirwan Peyman
Jochen Knolle
Thomas R Gadek
Jean-Francois Gourvest
Jean-Marie Ruxer
Original Assignee
Aventis Pharma Gmbh
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh, Genentech Inc filed Critical Aventis Pharma Gmbh
Publication of BR0012050A publication Critical patent/BR0012050A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DERIVADOS DE PURINA SUBSTITUìDA COMO INIBIDORES DA ADESãO CELULAR". A presente invenção diz respeito a compostos da fórmula 1, em que B, D, E, G, X, Y, Z, R^ 1^, R^ 2^ e s têm os significados indicados nas reivindicações, seus sais fisiologicamente toleráveis e seus pró-medicamentos. Os compostos da fórmula 1 são compostos farmacologicamente ativos valiosos. Eles são antagonistas receptores da vitronectina e inibidores da adesão celular e são adequados para a terapia e profilaxia de enfermidades que se baseiam na interação entre os receptores da vitronectina e seus ligandos nos processos de interação célula-célula ou célula matriz ou que podem ser prevenidas, aliviadas ou curadas mediante a influência de tais interações. Por exemplo, eles podem ser aplicados para inibir a reabsorção óssea por osteoclastos e assim para tratar e prevenir a osteoporose, ou para inibir a angiogênese indesejada ou proliferação de células da musculatura lisa vascular. A invenção além disso diz respeito a processos para a preparação de compostos da fórmula (1), seu uso, em particular como ingredientes ativos em produtos farmacêuticos e composições farmacêuticas compreendendo-os.
BR0012050-2A 1999-07-02 2000-06-26 Derivados de purina substituìda como inibidores da adesão celular BR0012050A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99112637A EP1065208A1 (en) 1999-07-02 1999-07-02 Substituted purine derivatives as inhibitors of cell adhesion
PCT/EP2000/005921 WO2001002399A1 (en) 1999-07-02 2000-06-26 Substituted purine derivatives as inhibitors of cell adhesion

Publications (1)

Publication Number Publication Date
BR0012050A true BR0012050A (pt) 2002-12-31

Family

ID=8238483

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012050-2A BR0012050A (pt) 1999-07-02 2000-06-26 Derivados de purina substituìda como inibidores da adesão celular

Country Status (30)

Country Link
US (1) US6747016B1 (pt)
EP (2) EP1065208A1 (pt)
JP (1) JP2003503497A (pt)
KR (1) KR20020015997A (pt)
CN (1) CN1171888C (pt)
AR (1) AR034242A1 (pt)
AT (1) ATE262528T1 (pt)
AU (1) AU774382B2 (pt)
BG (1) BG106229A (pt)
BR (1) BR0012050A (pt)
CA (1) CA2376673A1 (pt)
CZ (1) CZ20014553A3 (pt)
DE (1) DE60009296T2 (pt)
EA (1) EA005372B1 (pt)
EE (1) EE200100713A (pt)
ES (1) ES2219353T3 (pt)
HU (1) HUP0300183A3 (pt)
IL (1) IL147245A0 (pt)
MX (1) MXPA01013241A (pt)
MY (1) MY122631A (pt)
NO (1) NO20016403L (pt)
NZ (1) NZ516095A (pt)
PL (1) PL352281A1 (pt)
SK (1) SK18792001A3 (pt)
TR (1) TR200103858T2 (pt)
TW (1) TWI229080B (pt)
UA (1) UA72923C2 (pt)
WO (1) WO2001002399A1 (pt)
YU (1) YU89701A (pt)
ZA (1) ZA200200017B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042655A1 (de) 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
ES2684821T3 (es) * 2005-12-29 2018-10-04 Lexicon Pharmaceuticals, Inc. Derivados de aminoácidos multicíclicos y métodos de su uso
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CN107450106A (zh) * 2017-09-28 2017-12-08 北京小米移动软件有限公司 饮水安全提示方法、装置及智能水杯
AU2021267373A1 (en) 2020-05-06 2022-12-08 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2022140527A1 (en) 2020-12-23 2022-06-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
EP4430042A1 (en) 2021-11-09 2024-09-18 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2190870A1 (en) * 1994-05-27 1995-12-07 George D. Hartman Compounds for inhibiting osteoclast-mediated bone resorption
AU724191B2 (en) * 1996-08-29 2000-09-14 Merck & Co., Inc. Integrin antagonists
EP0946164A4 (en) * 1996-10-30 2000-08-23 Merck & Co Inc INTEGRIN ANTAGONISTS
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
CA2277273C (en) * 1997-01-17 2008-03-25 Merck & Co., Inc. Integrin antagonists
SK10632000A3 (sk) * 1998-01-23 2001-02-12 Aventis Pharma Deutschland Gmbh Sulfónamidové deriváty ako inhibítory resorpcie kostí a inhibítory bunkovej adhézie
WO1999038621A1 (en) 1998-01-28 1999-08-05 Danmist Aps Method of piezoelectrically atomising and pumping fluids and piezoelectric fluid atomising and pumping device

Also Published As

Publication number Publication date
BG106229A (bg) 2002-08-30
EA200200121A1 (ru) 2002-06-27
UA72923C2 (uk) 2005-05-16
CZ20014553A3 (cs) 2002-06-12
TWI229080B (en) 2005-03-11
HUP0300183A3 (en) 2005-12-28
IL147245A0 (en) 2002-08-14
EP1065208A1 (en) 2001-01-03
HUP0300183A2 (hu) 2003-06-28
NO20016403L (no) 2002-03-01
ES2219353T3 (es) 2004-12-01
MXPA01013241A (es) 2002-06-21
EP1196416A1 (en) 2002-04-17
AU5534900A (en) 2001-01-22
CN1371376A (zh) 2002-09-25
DE60009296D1 (de) 2004-04-29
TR200103858T2 (tr) 2002-06-21
EP1196416B1 (en) 2004-03-24
KR20020015997A (ko) 2002-03-02
ATE262528T1 (de) 2004-04-15
CA2376673A1 (en) 2001-01-11
NZ516095A (en) 2004-08-27
ZA200200017B (en) 2003-01-02
JP2003503497A (ja) 2003-01-28
CN1171888C (zh) 2004-10-20
NO20016403D0 (no) 2001-12-28
MY122631A (en) 2006-04-29
WO2001002399A1 (en) 2001-01-11
PL352281A1 (en) 2003-08-11
EE200100713A (et) 2003-04-15
US6747016B1 (en) 2004-06-08
YU89701A (sh) 2004-09-03
SK18792001A3 (sk) 2002-07-02
EA005372B1 (ru) 2005-02-24
AU774382B2 (en) 2004-06-24
DE60009296T2 (de) 2005-05-25
AR034242A1 (es) 2004-02-18

Similar Documents

Publication Publication Date Title
BR9814308A (pt) Derivados de acilguanidina como inibidores de ressorção óssea e como antagonistas de receptores de vitronectina
BR9907735A (pt) Derivados de sulfonamida como inibidores da reabsorção óssea e como inibidores da aderência celular
BR9706387A (pt) Derivados de purina substituìdos, processos para a sua preparação, seu emprego e composições contendo os mesmos
BR0012050A (pt) Derivados de purina substituìda como inibidores da adesão celular
BR0012129A (pt) Derivados de naftiridina, processos para sua preparação, seu uso e composições farmacêuticas compreendendo-os
BR0213562A (pt) Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
NO20032905D0 (no) Nye benzodiazepiner og beslektede heterocykliske derivater som er anvendelige som orexinreseptorantagonister
BR0014760A (pt) Derivados de purina
MX9504630A (es) Nuevos derivados de la oxazolidinona, antagonista del receptor de adhesion, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
BR0011705A (pt) Derivados de purina
BR0312648A (pt) Processo para preparação de certos compostos pirrolo triazina
BRPI0109200B8 (pt) compostos e composições farmacêuticas
Chung et al. Synthesis of 1-β-d-ribofuranosyl-3-ethynyl-[1, 2, 4] triazole and its in vitro and in vivo efficacy against Hantavirus
CA2371789A1 (en) Novel guanidine derivatives as inhibitors of cell adhesion
Ferretti et al. Biomechanical effects of the full range of useful doses of (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD) on femur diaphyses and cortical bone tissue in rats
BR0009561A (pt) 1,4-didro indeno [1,2-c] pirazóis substituìdos como inbidores de tirosina cinase
BR0317003A (pt) Derivados de imidazol como inibidores do fator xa
Li et al. Preadministration of incadronate disodium can prevent bone loss in rat proximal tibial metaphysis when induced by hindlimb immobilization by bandage
BR0207981A (pt) Derivados de imidazolidina, sua preparação, e seu uso como agente antiinflamatório
AU2674201A (en) Thienylalanine derivatives as inhibitors of cell adhesion
MXPA02006250A (es) Derivados de butino diol.
DE60138893D1 (pt)
AR023989A1 (es) DERIVADOS DE ESPIROIMIDAZOLIDINA, SU PROCESO DE PREPARACIoN , LAS COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU UTILIZACIoN PARA LA PREPARACIoN DE UN MEDICAMENTO.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A,8A E 9A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.